成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

  2. PI3K/Akt/mTOR Autophagy
  3. PI3K Autophagy
  4. AZD 6482

AZD 6482  (Synonyms: KIN-193)

目錄號: HY-10344 純度: 99.93%
COA 產品使用指南 技術支持

AZD 6482 (KIN-193) 是一種有效的選擇性 p110β 抑制劑，IC50 為 0.69 nM。

MCE 的所有產品僅用作科學研究或藥證申報，我們不為任何個人用途提供產品和服務

AZD 6482 Chemical Structure

AZD 6482 Chemical Structure

CAS No. : 1173900-33-8

1.  客戶無需承擔相應的運輸費用。

2.  同一機構（單位）同一產品試用裝僅限申領一次，同一機構（單位）一年內

     可免費申領三個不同產品的試用裝。

3.  試用裝只面向終端客戶。

規(guī)格 價格 是否有貨 數量
10 mM * 1 mL in DMSO ￥810
In-stock
1 mg ￥409
In-stock
5 mg ￥900
In-stock
10 mg ￥1500
In-stock
25 mg ￥2500
In-stock
50 mg ￥4500
In-stock
100 mg   詢價  
200 mg   詢價  

* Please select Quantity before adding items.

Customer Review

Other Forms of AZD 6482:

    AZD 6482 purchased from MCE. Usage Cited in: Cancer Lett. 2019 Jan;440-441:54-63.  [Abstract]

    The cells are transfected with either the negative control (siNC) or BTF3 siRNA for 12 hours followed by BKM-120 or AZD-6482 treatment for 48 hours. The protein abundance is determined by an immunoblotting analysis.

    AZD 6482 purchased from MCE. Usage Cited in: Oncol Rep. 2019 Jan;41(1):125-132.  [Abstract]

    The expression levels of Bcl-2, Bax and related proteins of the PI3K signalling pathway are used to assess the inhibitory effect of AZD6482. Each protein is analysed in triplicate, and a representative experiment is shown.

    AZD 6482 purchased from MCE. Usage Cited in: Cell Discov. 2016 Sep 20;2:16030.  [Abstract]

    Effects of combined inhibition of PI3K and STAT3 pathways on PTEN-mutated T-ALL cells. (a) Short-term treatment of Ba/F3-shPTEN-NTRK2-Tel cells with isoform-selective inhibitors and Pan-PI3K inhibitor GDC-0032. Cells are treated with DMSO, BYL719, KIN193, GS-1101, GDC-0032 (1?μM) or JAK–STAT inhibitor AZD-1480 (1?μM) for 3?h (n=3) for each treatment. (b) Immunoblot analysis of P-Akt and p-S6 in PF382 and JURKAT cells. Cells are treated with the same inhibitors as in a. (c) Combination of siNTRK2

    AZD 6482 purchased from MCE. Usage Cited in: Oncogene. 2016 Jul 7;35(27):3607-12.  [Abstract]

    (A) Immunoblot analyses in HCC1569 cells treated with BYL719, KIN193 (MedChemexpress) or BKM120 (μM). (B, C) Immunoblot analyses in BT474 and BT474-shPTEN cells treated as indicated in (A).

    AZD 6482 purchased from MCE. Usage Cited in: Tumour Biol. 2016 Nov;37(11):14831-14839.  [Abstract]

    Western blot analysis of PI3K signaling in NIC-PTENL/L cells treated with BYL719, AZD6482, or BKM120.

    AZD 6482 purchased from MCE. Usage Cited in: Nat Commun. 2015 Oct 7;6:8501.  [Abstract]

    Western blot analysis of Akt signalling in whole BM cells at 7 DPI. Freshly isolated BM cells are treated with DMSO, BYL719, KIN193, GS1101 or NVSPI35 at the 1-μM dose for 2?h (n=6) for each treatment.

    AZD 6482 purchased from MCE. Usage Cited in: Cancer Discov. 2012 May;2(5):425-33.  [Abstract]

    Effects of KIN-193, GDC-0941, PIK-75 and IC87114 on AKT phosphorylation in PTEN-deficient cell lines as indicated. Representative western blots are shown. Bar graphs represent mean ± SD of western blot quantitations of AKTT308 (n=3).

    • 生物活性

    • 實驗參考方法

    • 純度 & 產品資料

    • 參考文獻

    生物活性

    AZD 6482 (KIN-193) is a potent and selective p110β inhibitor with an IC50 of 0.69 nM.

    IC50 & Target[1]

    PI3Kβ

    0.69 nM (IC50)

    PI3Kδ

    13.6 nM (IC50)

    PI3Kγ

    47.8 nM (IC50)

    PI3Kα

    136 nM (IC50)

    PI3K-C2β

    54.1 nM (IC50)

    hVps34

    3390 nM (IC50)

    DNA-PK

    53.7 nM (IC50)

    mTOR

    3930 nM (IC50)

    PI4Kα

    8830 nM (IC50)

    Autophagy

     

    細胞效力
    (Cellular Effect)
    Cell Line Type Value Description References
    Platelet IC50
    0.27 μM
    Compound: 2, AZD6482
    Antiplatelet activity against human platelet assessed as inhibition of ADP-induced whole blood aggregation by light transmission aggregometry
    Antiplatelet activity against human platelet assessed as inhibition of ADP-induced whole blood aggregation by light transmission aggregometry
    		[PMID: 25042253]
    Platelet IC50
    1.4 μM
    Compound: 2, AZD6482
    Antiplatelet activity against dog platelet assessed as inhibition of ADP-induced whole blood aggregation by light transmission aggregometry
    Antiplatelet activity against dog platelet assessed as inhibition of ADP-induced whole blood aggregation by light transmission aggregometry
    		[PMID: 25042253]
    Platelet IC50
    280 nM
    Compound: 2, AZD6482
    Antiplatelet activity against human platelet assessed as inhibition of collagen-induced platelet rich plasma aggregation by light transmission aggregometry
    Antiplatelet activity against human platelet assessed as inhibition of collagen-induced platelet rich plasma aggregation by light transmission aggregometry
    		[PMID: 25042253]
    體外研究
    (In Vitro)

    體外激酶測定表明，AZD 6482 (KIN-193) 可高效抑制 p110β 的激酶活性 (IC50 為 0.69 nM)，選擇性是 p110α 的 200、20 和 70 倍、p110δ 和 p110γ 亞型。AZD 6482 的選擇性也比 PI3K-C2β 和 DNA-PK 高約 80 倍，比其他磷脂酰肌醇 3 激酶相關激酶 (PIKK) 高 1000 倍以上。使用 KinomeScan 方法對 AZD 6482 與一組 433 種激酶進行抑制劑-激酶相互作用分析表明，AZD 6482 在與 PI3K 的相互作用中具有高度選擇性。為確定 AZD 6482 是否選擇性靶向 PTEN 缺陷腫瘤，使用高通量腫瘤細胞系分析測試了 AZD 6482 對 422 癌細胞系的細胞增殖的影響。35% 的 PTEN 突變細胞系 (57 個中的 20 個) 和 16% 的野生型 PTEN 細胞系 (365 個中的 58 個) 對 AZD 6482 敏感，閾值為 EC50< 5 μM[1]。

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    體內研究
    (In Vivo)

    為了確定 AZD 6482 (KIN-193) 在體內腫瘤中的藥效學，大鼠成纖維細胞 (Rat1) 被設計為表達 p53DD (p53 的顯性失活突變體) 和組成型激活的 myr-p110β (Rat1-CA-p110β)，使這些細胞能夠在小鼠體內形成異種移植腫瘤。為了進行比較，還生成了表達 p53DD 和 myr-p110α (Rat1-CA-p110α) 的等基因 Rat1 細胞系。將 Rat1-CA-p110α 和 Rat1-CA-p110β 細胞皮下引入無胸腺小鼠的對側脅腹，這樣由活化的 p110α 或 p110β 驅動的腫瘤將暴露在相同的條件下，并且可以消除對動物間變異性的擔憂.當腫瘤達到約 500 mm3 的體積時，荷瘤小鼠接受單次腹腔注射；注射 AZD 6482 (10 mg/kg)。AZD 6482 的血漿濃度在注射后 1 小時達到最高，并在 4 小時內下降至檢測不到的水平。AZD 6482 在 CA-p110α 和 CA-p110β 驅動的腫瘤中的濃度與血漿濃度平行。對注射 AZD 6482 后不同時間點收集的腫瘤裂解物的分析表明，在注射 AZD 6482 后 1 小時，在 Rat1-CA-p110β 腫瘤中 AKT 的磷酸化顯著降低，但在 Rat1-CAp110α 腫瘤中保持不變[1]。

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    Clinical Trial
    分子量

    408.45

    Formula

    C22H24N4O4
    CAS 號
    性狀

    固體

    顏色

    White to light yellow

    運輸條件

    Room temperature in continental US; may vary elsewhere.
    儲存方式
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 2 years
    -20°C 1 year
    溶解性數據
    細胞實驗： 

    DMSO 中的溶解度 : 50 mg/mL (122.41 mM; 超聲助溶; 吸濕的 DMSO 對產品的溶解度有顯著影響，請使用新開封的 DMSO)

    配制儲備液
    濃度 溶劑體積 質量 1 mg 5 mg 10 mg
    1 mM 2.4483 mL 12.2414 mL 24.4828 mL
    5 mM 0.4897 mL 2.4483 mL 4.8966 mL
    查看完整儲備液配制表

    * 請根據產品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；一旦配成溶液，請分裝保存，避免反復凍融造成的產品失效。
    儲備液的保存方式和期限：-80°C, 2 years; -20°C, 1 year。-80°C儲存時，請在2年內使用， -20°C儲存時，請在1年內使用。

    • 摩爾計算器

    • 稀釋計算器

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    質量
    =
    濃度
    ×
    體積
    ×
    分子量 *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    濃度 (start)

    C1

    ×
    體積 (start)

    V1

    =
    濃度 (final)

    C2

    ×
    體積 (final)

    V2

    動物實驗：

    請根據您的 實驗動物和給藥方式 選擇適當的溶解方案。

    以下溶解方案都請先按照 In Vitro 方式配制澄清的儲備液，再依次添加助溶劑：
    ——為保證實驗結果的可靠性，澄清的儲備液可以根據儲存條件，適當保存；體內實驗的工作液，建議您現用現配，當天使用；
    以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比；如在配制過程中出現沉淀、析出現象，可以通過加熱和/或超聲的方式助溶

    • 方案 一

      請依序添加每種溶劑： 10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.5 mg/mL (6.12 mM); 澄清溶液

      此方案可獲得 ≥ 2.5 mg/mL（飽和度未知）的澄清溶液。

      以 1 mL 工作液為例，取 100 μL 25.0 mg/mL 的澄清 DMSO 儲備液加到 400 μL PEG300 中，混合均勻；再向上述體系中加入 50 μL Tween-80，混合均勻；然后再繼續(xù)加入 450 μL 生理鹽水 定容至 1 mL。

      生理鹽水的配制：將 0.9 g 氯化鈉，溶解于 ddH?O 并定容至 100 mL，可以得到澄清透明的生理鹽水溶液。
    • 方案 二

      請依序添加每種溶劑： 10% DMSO    90% Corn Oil

      Solubility: ≥ 2.5 mg/mL (6.12 mM); 澄清溶液

      此方案可獲得 ≥ 2.5 mg/mL（飽和度未知）的澄清溶液，此方案實驗周期在半個月以上的動物實驗酌情使用。

      以 1 mL 工作液為例，取 100 μL 25.0 mg/mL 的澄清 DMSO 儲備液加到 900 μL玉米油中，混合均勻。

    動物溶解方案計算器
    請輸入動物實驗的基本信息：

    給藥劑量

    mg/kg

    動物的平均體重

    g

    每只動物的給藥體積

    μL

    動物數量

    只
    由于實驗過程有損耗，建議您多配一只動物的量
    請輸入您的動物體內配方組成：
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    如果您的動物是免疫缺陷鼠或者體弱鼠，建議 DMSO 中的在最后工作液體系中的占比盡量不超過 2%。
    方案所需 助溶劑 包括：DMSO， ，均可在 MCE 網站選購。 ，Tween 80，均可在 MCE 網站選購。
    計算結果
    工作液所需濃度 : mg/mL
    儲備液配制方法 : mg 藥物溶于 μL  DMSO（母液濃度為 mg/mL）。
    您所需的儲備液濃度超過該產品的實測溶解度，以下方案僅供參考，如有需要，請與 MCE 中國技術支持聯(lián)系。
    動物實驗體內工作液的配制方法 : 取 μL DMSO 儲備液，加入 μL 。 μL ，混合均勻至澄清，再加 μL Tween 80，混合均勻至澄清，再加 μL 生理鹽水。
    連續(xù)給藥周期超過半月以上，請謹慎選擇該方案。
    請確保第一步儲備液溶解至澄清狀態(tài)，從左到右依次添加助溶劑。您可采用超聲加熱 （超聲清洗儀，建議頻次 20-40 kHz），渦旋吹打等方式輔助溶解。
    純度 & 產品資料

    純度: 99.93%

    參考文獻
    Kinase Assay
    [1]

    AZD 6482 (KIN-193) is profiled at a concentration of 10 μM against a diverse panel of 433 kinases. Scores for primary screen hits are reported as percent of the DMSO control (% control). For kinases where no score is shown, no measurable binding is detected. The lower the score, the lower the Kd is likely to be, such that scores of zero represent strong hits. Scores are related to the probability of a hit, but are not strictly an affinity measurement. At a screening concentration of 10 μM, a score of less than 10% implies that the false positive probability is less than 20% and the Kd is most likely less than 1 μM. A score between 1-10% implies that the false positive probability is less than 10%, although it is difficult to assign a quantitative affinity from a single-point primary screen. A score of less than 1% implies that the false positive probability is less than 5% and the Kd is most likely less than 1 μM[1].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    Cell Assay
    [1]

    Cell viability is determined. Briefly, cells are seeded in medium containing 5% FBS at a density insuring cell growth throughout drug treatment (~15% for most cell lines). Drug treatment is started 24 h post seeding and continued for 72 h. Cell are fixed and stained using Syto60, a red fluorescent DNA stain. The relative cell number is calculated by taking the ratio of the relative fluorescence intensity from drug treated wells over untreated wells after background subtraction (cells-free wells). Nine doses of AZD 6482 (KIN-193) are used in 2-fold dilution steps ranging from 5.12 μM to 0.02 μM. IC50, corresponding to 50% cell number compared to control (untreated) wells, is determined using a fixed top and bottom sigmoidal fitting algorithm implemented in PipelinePilot[1].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    Animal Administration
    [1]

    Mice[1]
    Approximately 6-8 week-old female nude mice are injected s.c. with Rat1-Myr-HA-p110α(Rat1-CAp110α) cells (1×106 cells in 40% matrigel) in one flank (site 1) and Rat1-Myr-HA-p110β (Rat1-CAp110β) cells (0.5×106 cells in 10% matrigel) in the contralateral flank (site 2). When tumors grow to ~500 mm3, mice are dosed once by ip injection with AZD 6482 formulated in 7.5% NMP, 40% PEG400, 52.5% dH2O at 0.1 mL/10g body weight and 10 mg/kg. Tumors are collected at 0, 1, 4, 8, and 24 h following compound administration and blood samples are obtained by direct heart puncture. Serum is separated and stored at -80°C. The drug concentrations in serum and tumor samples are assessed by LC-MS/MS analysis by the DMPK group.

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    參考文獻

    完整儲備液配制表

    * 請根據產品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；一旦配成溶液，請分裝保存，避免反復凍融造成的產品失效。
    儲備液的保存方式和期限：-80°C, 2 years; -20°C, 1 year。-80°C儲存時，請在2年內使用， -20°C儲存時，請在1年內使用。

    可選溶劑 濃度 溶劑體積 質量 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 2.4483 mL 12.2414 mL 24.4828 mL 61.2070 mL
    5 mM 0.4897 mL 2.4483 mL 4.8966 mL 12.2414 mL
    10 mM 0.2448 mL 1.2241 mL 2.4483 mL 6.1207 mL
    15 mM 0.1632 mL 0.8161 mL 1.6322 mL 4.0805 mL
    20 mM 0.1224 mL 0.6121 mL 1.2241 mL 3.0604 mL
    25 mM 0.0979 mL 0.4897 mL 0.9793 mL 2.4483 mL
    30 mM 0.0816 mL 0.4080 mL 0.8161 mL 2.0402 mL
    40 mM 0.0612 mL 0.3060 mL 0.6121 mL 1.5302 mL
    50 mM 0.0490 mL 0.2448 mL 0.4897 mL 1.2241 mL
    60 mM 0.0408 mL 0.2040 mL 0.4080 mL 1.0201 mL
    80 mM 0.0306 mL 0.1530 mL 0.3060 mL 0.7651 mL
    100 mM 0.0245 mL 0.1224 mL 0.2448 mL 0.6121 mL
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    您最近查看的產品:

    Your information is safe with us. * Required Fields.

       產品名稱：

    		  

    * 需求量：

    * 客戶姓名：

    		 

    * Email：

    * 電話：

    		 

    * 公司或機構名稱：

       留言給我們：

    Bulk Inquiry

    Inquiry Information

    產品名稱：
    AZD 6482
    目錄號：
    HY-10344
    需求量：